Weng C Chan

Title: Weng C Chan: Innovator in p21 Peptides

Introduction

Weng C Chan is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of biochemistry, particularly through his work on p21 derived peptides. His innovative approach has led to advancements in understanding the inhibition of CDK/cyclin complexes.

Latest Patents

Weng C Chan holds a patent related to p21 peptides. The present invention focuses on peptides capable of inhibiting CDK/cyclin complexes, specifically targeting cyclins A or E/CDK2. These peptides are derived from the C-terminal region of p21 and exhibit selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Notably, variants of these peptides, especially those involving certain alanine replacements, have shown to be particularly potent. He has 1 patent to his name.

Career Highlights

Weng C Chan is associated with Cyclacel Limited, a company that focuses on developing innovative cancer therapies. His work has been instrumental in advancing the understanding of cell cycle regulation and its implications for cancer treatment.

Collaborations

Weng has collaborated with notable colleagues, including Daniella I Zheleva and Peter Martin Fischer. These collaborations have contributed to the development of his research and innovations in the field.

Conclusion

Weng C Chan's contributions to the field of biochemistry, particularly through his work on p21 peptides, highlight his role as an innovator. His patent and collaborations reflect his commitment to advancing scientific knowledge and therapeutic options.